Hey readers!
Here's a detail that surprised me in the new British Society of Gastroenterology guidelines: before you get tested for celiac disease, you're supposed to eat gluten on purpose, and the guideline now puts a number on it. That gluten-challenge dose, plus a clearer follow-up timeline and a first-line plan for refractory cases, is what we're unpacking this week. If you're a clinician, a patient, or a parent trying to make sense of what testing should actually look like, this is the issue to bookmark.
📋 What the 2026 BSG guidelines actually change
Latest BSG guidelines set out celiac disease diagnostic and management pathway lays out the most practical version of the update: a formalized diagnostic pathway and a structured follow-up plan, including for patients with refractory disease. – springermedicine.com
This matters because so much of the confusion around celiac diagnosis comes from testing done at the wrong time or without the right sequence. The guideline development process drew on extensive post-2014 literature and translated it into recommendations, good practice statements, and expert opinions, so this is a genuine refresh rather than a light edit.
Here's the diagnostic pathway in plain terms:
Eat gluten before testing. Patients should consume 3-6 g/day of gluten for at least 6 weeks before testing. If you've already gone gluten-free, this is the step people most often skip, and it's the one that produces false negatives.
Start with IgA-tTG. IgA-tissue transglutaminase antibody testing is used first, with screening for selective IgA deficiency.
Adjust if IgA-deficient. When IgA deficiency is present, the guideline calls for IgG-based celiac serology plus upper GI endoscopy with duodenal biopsies.
Confirm with histology. Diagnosis requires positive serology plus duodenal biopsy findings showing intraepithelial lymphocytes (IELs) greater than 25 per 100 epithelial cells with crypt hyperplasia, with or without villous atrophy.
On that last point, the guideline is explicit about what those biopsy findings represent:
"equates to a Marsh 2 or 3 histology grading stage."
The takeaway for patients: don't let anyone diagnose or rule out celiac disease off a single antibody test while you're already avoiding gluten. Serology and histology work together, and the timing of your gluten intake is part of the test.
🩺 Follow-up isn't a one-and-done
The part I wish more people knew is that diagnosis is the beginning, not the finish line. The BSG guideline pairs the gluten-free diet (GFD) with a structured assessment of adherence rather than assuming the diet alone solves everything.
What structured follow-up looks like under the new guidance:
Adherence is actively checked, via specialist dietician review and symptom assessment, not left to guesswork.
Regular follow-up for 2 years, with monitoring for nutrient deficiencies.
A DEXA scan 1 year after starting a gluten-free diet, to catch the bone-density fallout that celiac disease can quietly cause.
For clinicians, this formalizes something good practices already did informally. For patients and parents, it's a checklist you can bring to appointments: ask whether a dietician review is scheduled, whether your nutrient levels are being tracked, and when your DEXA scan is planned. These are now framed as expected parts of care, so it's fair to expect them.
💊 Refractory disease gets a clearer plan
Refractory celiac disease, where symptoms persist despite a strict gluten-free diet, is one of the hardest situations to manage, and the guideline now stages it.
First-line management is open-capsule budesonide alongside a strict GFD. From there, treatment is individualized: depending on the case and stage, it may include steroid-sparing immunosuppressants such as azathioprine, with flow cytometry used for second-line disease, all within multidisciplinary care.
The practical signal here is that refractory disease should not be handled in isolation. If a gluten-free diet isn't working and everything's been double-checked for hidden exposure, the guideline points toward specialist, team-based evaluation rather than simply trying harder on the diet.
🌍 Who wrote it, and why the timing
The 2026 British Society of Gastroenterology guidelines on the diagnosis and management of adult coeliac disease gives the backstory: the update was built by a multidisciplinary panel with contributors from the UK, Sweden, Italy, and Australia, prompted by recent advances in diagnosing and treating adult celiac disease. – 2 Medical News
That international, cross-disciplinary makeup is worth noting. Guidelines assembled by a broad panel tend to travel well beyond their home country, so clinicians outside the UK will likely find these recommendations relevant to their own practice. The stated goal is straightforward: emphasize evidence-based practices to improve how adult celiac disease is managed and to enhance patient care.
🔮 What's coming next
One of the most forward-looking lines in the coverage is about where treatment is heading beyond the diet. The guideline is candid that drugs haven't yet replaced the gluten-free diet, but it doesn't close the door either:
Whether drugs can provide an effective alternative to the GFD remains to be determined, but it is likely that therapies which provide relief for occasional and/or inadvertent gluten exposure will be introduced to the management of [celiac disease] in the near future.
That's a measured, honest framing. For now, the gluten-free diet remains the foundation. But the guideline is openly anticipating adjunct therapies aimed at the accidental exposures that even the most careful patients run into. If you've ever agonized over a cross-contaminated meal, that's the gap future treatments are being designed to cover.
🍽️ Living gluten-free in the meantime
Until those therapies arrive, the everyday challenge stays the same: finding food you can trust. One resource worth keeping on your phone is Find Me Gluten Free (findmeglutenfree.com), which helps with locating safe gluten-free restaurants, food, and travel options. We're not sponsored by them; it's just a genuinely handy tool for the parts of life the guidelines can't cover.
And if you take one thing from this issue, let it be the gluten-challenge step. Whether you're a patient asking to be tested or a clinician ordering the workup, confirming that gluten intake was adequate before serology and biopsy is the difference between a clear answer and months of uncertainty.
Thanks for reading, and take good care of yourselves out there.